MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$11,330K
Free Cash flow
-$31,927K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from private placement
Proceeds from maturities and sal...
Accrued liabilities
Others
Negative Cash Flow Breakdown
Purchases of short-term investme...
Accounts receivable, net
Payment of private placement iss...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Net loss
-36,682
-15,109
-17,200
-23,171
Share-based compensation expense
2,460
917
916
1,893
Depreciation and amortization
325
181
179
344
Accretion of discounts on available-for-sale investments
10
67
169
537
Impairment of property and equipment
-
0
-
-
Loss on disposal of property and equipment
0
-3
0
-34
Accounts receivable, net
2,923
-4
17
-789
Prepaid expenses and other current assets
-2,373
-1,225
1,811
3,524
Other non-current assets
-3
599
-1
7
Accounts payable
52
-30
-300
1,952
Accrued liabilities
2,657
2,228
999
131
Contract liabilities
-167
2
1
0
Operating lease liabilities
-8
-1
-1
56
Contract assets
-
-
-
0
Other non-current liabilities
-7
-4
-4
-510
Net cash used in operating activities
-31,927
-11,250
-17,406
-22,550
Purchases of short-term investments
4,469
0
0
30,470
Proceeds from maturities and sales of short-term investments
6,000
11,000
14,380
15,340
Purchases of property and equipment
0
16
34
384
Proceeds from sale of property and equipment
0
0
0
2
Net cash provided by (used in) investing activities
1,531
10,984
14,346
-15,512
Proceeds from private placement
20,154
-
-
-
Payment of private placement issuance costs
1,518
-
-
-
Proceeds from shares issued under the employee share purchase plan
-
75
0
143
Proceeds from purchases under the employee stock purchase plan
176
-
-
-
Proceeds from exercise of stock options
-
640
215
20
Proceeds from issuances of ordinary shares under the stock incentive plan
137
-
-
-
Net cash provided by financing activities
18,949
715
215
163
Effect of exchange rate changes on cash and cash equivalents
117
51
58
299
Net decrease in cash and cash equivalents
-11,330
500
-2,787
-37,600
Cash and cash equivalents at beginning of period
38,345
37,845
78,232
-
Cash and cash equivalents at end of period
27,015
38,345
37,845
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from private
placement
$20,154K
Proceeds from maturities
and sales of...
$6,000K
(-60.89%↓ Y/Y)
Proceeds from purchases
under the employee...
$176K
Proceeds from issuances
of ordinary shares...
$137K
Net cash provided by
financing activities
$18,949K
(11525.15%↑ Y/Y)
Net cash provided by
(used in) investing...
$1,531K
(109.87%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$117K
(-60.87%↓ Y/Y)
Canceled cashflow
$1,518K
Canceled cashflow
$4,469K
Net decrease in cash
and cash...
-$11,330K
(69.87%↑ Y/Y)
Canceled cashflow
$20,597K
Accrued liabilities
$2,657K
(1928.24%↑ Y/Y)
Share-based compensation
expense
$2,460K
(29.95%↑ Y/Y)
Prepaid expenses and
other current assets
-$2,373K
(-167.34%↓ Y/Y)
Depreciation and
amortization
$325K
(-5.52%↓ Y/Y)
Accounts payable
$52K
(-97.34%↓ Y/Y)
Other non-current
assets
-$3K
(-142.86%↓ Y/Y)
Payment of private
placement issuance costs
$1,518K
Purchases of short-term
investments
$4,469K
(-85.33%↓ Y/Y)
Net cash used in
operating activities
-$31,927K
(-41.58%↓ Y/Y)
Canceled cashflow
$7,870K
Net loss
-$36,682K
(-58.31%↓ Y/Y)
Accounts receivable, net
$2,923K
(470.47%↑ Y/Y)
Contract liabilities
-$167K
Accretion of discounts on
available-for-sale investments
$10K
(-98.14%↓ Y/Y)
Operating lease
liabilities
-$8K
(-114.29%↓ Y/Y)
Other non-current
liabilities
-$7K
(98.63%↑ Y/Y)
Buy us a coffee
Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd (CNTB)